


-79-

Claims

1. A compound of formula (1):



(1)

5


wherein:

A is phenylene or heteroarylene;

n is 0, 1 or 2;

m is 0, 1 or 2;

- 10 R^1 is independently selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, *N*- C_{1-4} alkylcarbamoyl, *N,N*-(C_{1-4} alkyl) $_2$ carbamoyl, sulphamoyl, *N*- C_{1-4} alkylsulphamoyl, *N,N*-(C_{1-4} alkyl) $_2$ sulphamoyl, -S(O) $_b$ C_{1-4} alkyl (wherein b is 0, 1, or 2), C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, hydroxy C_{1-4} alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy;
- 15 or, when n is 2, the two R^1 groups, together with the carbon atoms of A to which they are attached, may form a 4 to 7 membered ring, optionally containing 1 or 2 heteroatoms independently selected from O, S and N, and optionally being substituted by one or two methyl groups;
- R^4 is independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy and C_{1-4} alkanoyl;
- 20 r is 1 or 2; and
- when r is 1 the group




- 25 is a substituent on carbon (2) and

-80-


when r is 2 (thereby forming a six membered ring) the same group is a substituent on carbon (2) or on carbon (3);

Y is $-NR^2R^3$ or $-OR^3$;

R^2 and R^3 are independently selected from hydrogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkanoyl, carbamoyl, C_{3-7} cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), cyano(C_{1-4})alkyl, heterocyclyl, aryl, C_{1-4} alkyl [optionally substituted by 1 or 2 R^8 groups], $-COR^8$, $-SO_bR^8$ (wherein b is 0, 1 or 2) and groups of the formulae B and B':



(B)



(B')

wherein y is 0 or 1, t is 0, 1, 2 or 3 and u is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen; or

wherein NR^2R^3 may form a 4 to 7 membered saturated, partially saturated or unsaturated ring, optionally containing 1, 2 or 3 additional heteroatoms independently selected from N, O and S, wherein any $-CH_2-$ may optionally be replaced by $-C(=O)-$, and any N or S atom may optionally be oxidised to form an N-oxide or SO or SO_2 group respectively, and wherein the ring is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy and $C_{1-4}alkylS(O)_b-$ (wherein b is 0, 1 or 2);

R^8 is independently selected from hydrogen, hydroxy, C_{1-4} alkyl, C_{2-4} alkenyl,

C_{1-4} alkoxy, cyano(C_{1-4})alkyl, amino(C_{1-4})alkyl [optionally substituted on nitrogen by 1 or 2 groups selected from C_{1-4} alkyl, hydroxy, hydroxy(C_{1-4})alkyl, dihydroxy(C_{1-4})alkyl, $-CO_2C_{1-4}$ alkyl, aryl and aryl(C_{1-4})alkyl], halo(C_{1-4})alkyl, dihalo(C_{1-4})alkyl, trihalo(C_{1-4})alkyl, hydroxy(C_{1-4})alkyl, dihydroxy(C_{1-4})alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, C_{1-4} alkoxy C_{1-4} alkyl, hydroxy C_{1-4} alkoxy, 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, aryl, heterocyclyl, (heterocyclyl) C_{1-4} alkyl, C_{3-7} cycloalkyl (optionally substituted with 1 or 2 hydroxy groups, C_{1-4} alkyl or $-C(O)OC_{1-4}$ alkyl), C_{1-4} alkanoyl, $C_{1-4}alkylS(O)_b-$ (wherein b is 0, 1 or 2), C_{3-6} cycloalkyl $S(O)_b-$ (wherein b is 0, 1 or 2), aryl $S(O)_b-$ (wherein b is 0, 1 or 2), heterocyclyl $S(O)_b-$ (wherein b is 0, 1 or 2), benzyl $S(O)_b-$ (wherein b is 0, 1 or 2),

-81-

$C_{1-4}alkylS(O)_c(C_{1-4}alkyl)$ (wherein c is 0, 1 or 2), $-N(OH)CHO$, $-C(=N-OH)NH_2$,
 $-C(=N-OH)NHC_{1-4}alkyl$, $-C(=N-OH)N(C_{1-4}alkyl)_2$, $-C(=N-OH)NHC_{3-6}cycloalkyl$,
 $-C(=N-OH)N(C_{3-6}cycloalkyl)_2$, $-COCOOR^9$, $-C(O)N(R^9)(R^{10})$, $-NHC(O)R^9$,
 $-C(O)NHSO_2(C_{1-4}alkyl)$, $-NHSO_2R^9$, $(R^9)(R^{10})NSO_2-$, $-COCH_2OR^{11}$, $(R^9)(R^{10})N-$ and
 5 $-COOR^9$, $-CH_2OR^9$, $-CH_2COOR^9$, $-CH_2OCOR^9$, $-CH_2CH(CO_2R^9)OH$, $-CH_2C(O)NR^9R^{10}$,
 $-(CH_2)_wCH(NR^9R^{10})CO_2R^9$ (wherein w is 1, 2 or 3), $-(CH_2)_wCH(NR^9R^{10})CO(NR^9R^{10})$
 (wherein w is 1, 2 or 3);

R^9 , R^9 , R^{10} and R^{10} are independently selected from hydrogen, hydroxy, $C_{1-4}alkyl$
 (optionally substituted by 1 or 2 R^{13}), $C_{2-4}alkenyl$, $C_{3-7}cycloalkyl$ (optionally substituted by 1
 10 or 2 hydroxy groups), cyano($C_{1-4}alkyl$), trihaloalkyl, aryl, heterocyclyl, heterocyclyl($C_{1-4}alkyl$),
 $-C(=O)O(C_{1-4}alkyl)$; or

R^9 and R^{10} together with the nitrogen to which they are attached, and/or R^9 and R^{10}
 together with the nitrogen to which they are attached, form a 4- to 6-membered ring where the
 ring is optionally substituted on carbon by 1 or 2 substituents independently selected from
 15 oxo, hydroxy, carboxy, halo, nitro, cyano, carbonyl, $C_{1-4}alkoxy$ and heterocyclyl; or the ring
 may be optionally substituted on two adjacent carbons by $-O-CH_2-O-$ to form a cyclic acetal
 wherein one or both of the hydrogens of the $-O-CH_2-O-$ group may be replaced by a methyl;

R^{13} is selected from halo, trihalomethyl, and $C_{1-4}alkoxy$;

R^{11} is independently selected from hydrogen, $C_{1-4}alkyl$, and hydroxy $C_{1-4}alkyl$;

20 or a pharmaceutically acceptable salt or pro-drug thereof.

2. A compound of formula (1) as claimed in claim 1, wherein:

R^2 and R^3 are independently selected from hydrogen, hydroxy, $C_{1-4}alkyl$ [optionally
 substituted by 1 or 2 R^8 groups], $C_{3-7}cycloalkyl$ (optionally substituted with 1 or 2 hydroxy
 25 groups), cyano($C_{1-4}alkyl$), phenyl, morpholino, morpholinyl, piperidino, piperidyl, pyridyl,
 pyranyl, pyrrolyl, imidazolyl, thiazolyl, thienyl, thiadiazolyl, piperazinyl, isothiazolidinyl,
 1,3,4-triazolyl, tetrazolyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl,
 3,5-dioxapiperidinyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrazolyl, pyrazolinyl, isoxazolyl, 4-
 oxopyridyl, 2-oxopyrrolidyl, 4-oxothiazolidyl, furyl, thienyl, oxazolyl, 1,3,4-oxadiazolyl, and
 30 1,2,4-oxadiazolyl, tetrahydrothiopyranyl, 1-oxotetrahydrothiopyranyl, 1,1-
 dioxotetrahydrothiopyranyl, $-COR^8$ and $-SO_bR^8$ (wherein b is 0, 1 or 2);

R^8 is independently selected from hydrogen, hydroxy, $C_{1-4}alkoxy$, $C_{1-4}alkoxyC_{1-4}alkyl$,
 $C_{1-4}alkoxyC_{1-4}alkoxy$, hydroxy $C_{1-4}alkoxy$, $C_{1-4}alkyl$, , amino($C_{1-4}alkyl$) [optionally substituted

-82-

- on nitrogen by 1 or 2 groups selected from C₁₋₄alkyl, hydroxy(C₁₋₄)alkyl, dihydroxy(C₁₋₄)alkyl, -CO₂C₁₋₄alkyl, aryl and aryl(C₁₋₄)alkyl], C₂₋₄alkenyl, C₃₋₇cycloalkyl (optionally substituted by -C(O)OC₁₋₄alkyl), 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, halo(C₁₋₄)alkyl, dihalo(C₁₋₄)alkyl, trihalo(C₁₋₄)alkyl, hydroxy(C₁₋₄)alkyl,
- 5 dihydroxy(C₁₋₄)alkyl, cyano(C₁₋₄)alkyl, heterocyclyl, heterocyclylC₁₋₄alkyl, aryl, C₁₋₄alkylS(O)_b- (wherein b is 0, 1 or 2), C₃₋₆cycloalkylS(O)_b- (wherein b is 0, 1 or 2), arylS(O)_b- (wherein b is 0, 1 or 2), heterocyclylS(O)_b- (wherein b is 0, 1 or 2), benzylS(O)_b- (wherein b is 0, 1 or 2), C₁₋₄alkylS(O)_c(C₁₋₄)alkyl (wherein c is 0, 1 or 2), -CH₂CH(NR⁹R¹⁰)CO(NR⁹R¹⁰), -CH₂OR⁹, (R⁹)(R¹⁰)N-, -COOR⁹, -CH₂COOR⁹,
- 10 -C(O)N(R⁹)(R¹⁰), -CH₂CH(CO₂R⁹)OH, -CH₂CONR⁹R¹⁰, -CH₂CH(NR⁹R¹⁰)CO₂R⁹ and -CH₂OCOR⁹;

- R⁹, R^{9'}, R¹⁰ and R^{10'} are independently selected from hydrogen, C₁₋₄alkyl (optionally substituted by 1 or 2 R¹³), C₃₋₇cycloalkyl (optionally substituted by 1 or 2 hydroxy groups), -C(=O)O^tBu, C₂₋₄alkenyl, cyano(C₁₋₄)alkyl, phenyl (optionally substituted by 1 or 2 groups
- 15 selected from nitro, halo, hydroxy and cyano); or

- R⁹ and R¹⁰ together with the nitrogen to which they are attached, and/or R^{9'} and R^{10'} together with the nitrogen to which they are attached, form a 4- to 6-membered ring where the ring is optionally substituted on carbon by 1 or 2 substituents independently selected from oxo, hydroxy, carboxy, halo, nitro, cyano, carbonyl and C₁₋₄alkoxy; or the ring may be
- 20 optionally substituted on two adjacent carbons by -O-CH₂-O- to form a cyclic acetal wherein one or both of the hydrogens of the -O-CH₂-O- group may be replaced by a methyl;

R¹³ is selected from halo, trihalomethyl, and C₁₋₄alkoxy;

or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

- 25 3. A compound of formula (1) as claimed in claim 1 or claim 2, wherein:

R² and R³ are independently selected from hydrogen, C₁₋₄alkyl [optionally substituted by 1 or 2 R⁸ groups], -COR⁸ and -SO_bR⁸ (wherein b is 0, 1 or 2);

- R⁸ is independently selected from hydrogen, hydroxy, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkyl, amino(C₁₋₄)alkyl [optionally substituted on nitrogen by 1 or 2 groups selected from
- 30 C₁₋₄alkyl, hydroxy(C₁₋₄)alkyl, dihydroxy(C₁₋₄)alkyl, -CO₂C₁₋₄alkyl, phenyl and aryl(C₁₋₄)alkyl], C₂₋₄alkenyl, C₃₋₇cycloalkyl (optionally substituted by -C(O)OC₁₋₄alkyl), 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, halo(C₁₋₄)alkyl, trihalo(C₁₋₄)alkyl, hydroxy(C₁₋₄)alkyl, dihydroxy(C₁₋₄)alkyl, cyano(C₁₋₄)alkyl, furyl (optionally

-83-

- substituted on carbon by 1 or 2 nitro groups), thienyl (optionally substituted on carbon by 1 or 2 nitro groups), morpholino, furyl(C₁₋₄)alkyl (wherein furyl is optionally substituted on carbon by 1 or 2 nitro groups), thienyl(C₁₋₄)alkyl (wherein thienyl is optionally substituted on carbon by 1 or 2 nitro groups), 1,2,4-oxadiazolyl, tetrazolyl, imidazolyl, pyrrolidinyl, piperidyl,
- 5 pyridyl, tetrahydrofuryl, tetrahydropyranyl, 1-oxo-tetrahydrothiopyranyl, tetrahydrothienyl, phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, cyano, hydroxy and C₁₋₄alkyl), pyrazinyl, piperazinyl, 4-methylpiperazino, C₁₋₄alkylS(O)_b- (wherein b is 0, 1 or 2), C₃₋₆cycloalkylS(O)_b- (wherein b is 0, 1 or 2), arylS(O)_b- (wherein b is 0, 1 or 2), heterocyclylS(O)_b- (wherein b is 0, 1 or 2 -CH₂CH(NR⁹R¹⁰)CO(NR⁹R¹⁰), -CH₂OR⁹,
- 10 (R⁹)(R¹⁰)N-, -COOR⁹, -CH₂COOR⁹, -C(O)N(R⁹)(R¹⁰), -CH₂CH(CO₂R⁹)OH, -CH₂CONR⁹R¹⁰, -CH₂CH(NR⁹R¹⁰)CO₂R⁹ and -CH₂OCOR⁹;

R⁹, R^{9'}, R¹⁰ and R^{10'} are independently selected from hydrogen, C₁₋₄alkyl (optionally substituted by 1 or 2 hydroxy groups), C₂₋₄alkenyl, and phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, hydroxy and cyano); or a pharmaceutically acceptable salt

15 or an in-vivo hydrolysable ester thereof.

4. A compound of the formula (1) as claimed in any preceding claim, wherein Y is NR²R³; or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

20 5. A compound of the formula (1) as claimed in any one of claims 1 to 3, wherein Y is OR³; or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

6. A compound of the formula (1) as claimed in any preceding claim wherein m is 1 and R⁴ is chlorine; or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.


25

7. A compound of the formula (1) as claimed in any preceding claim wherein A is phenylene; or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

8. A compound of the formula (1) as claimed in any one of claims 1 to 7 wherein A is

30 heteroarylene; or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

9. A compound of the formula (1) as claimed in any preceding claim, which is a compound of formula (1A):



(1A)

or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

- 5 10. A compound of the formula (1) as claimed in claim 1, which is any one of:
- 5-chloro-2-[*N*-(1-hydroxyindan-2-yl)carbamoyl]indole;
- 5-chloro-*N*-{(1*R*,2*R*)-1-[(methylsulfonyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-
- carboxamide;
- N*-{(1*R**, 2*R**)-1-[(2-carboxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-
- 10 carboxamide;
- 5-chloro-*N*-{(1*R*,2*R*)-1-[(3-methoxypropanoyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-
- indole-2-carboxamide;
- N*-[(1*R*,2*R*)-1-(acetylamino)-2,3-dihydro-1*H*-inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide;
- 5-chloro-*N*-[(1*R*,2*R*)-1-(*tert*-butoxycarbonylaminoacetamido)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-
- 15 indole-2-carboxamide;
- N*-[(1*R*,2*R*)-1-{[3-(*tert*-butoxycarbonylamino)-4-oxopentanoyl]amino}-2,3-dihydro-1*H*-
- inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide;
- N*-{(1*R*,2*R*)-1-[(2-carbamoylacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-
- carboxamide;
- 20 *N*-{(1*R*,2*R*)-1-[(2-carboxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-
- carboxamide;
- 5-chloro-*N*-{(1*R*,2*R*)-1-[(hydroxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-
- carboxamide;
- 2-chloro-*N*-[(1*R*,2*R*)-1-{[3-hydroxy-2-(hydroxymethyl)propanoyl]amino}-2,3-dihydro-1*H*-
- 25 inden-2-yl]-1*H*-indole-2-carboxamide;
- N*-[(1*R*,2*R*)-1-[(3*R*)-3-amino-3-carbamoylpropanoyl]amino]-2,3-dihydro-1*H*-inden-2-yl}-5-
- chloroindole-2-carboxamide;
- N*-{(1*R*,2*R*)-1-[(aminoacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-
- carboxamide;

-85-

- 5-chloro-*N*-{(1*S*,2*S*)-1-[(methylsulfonyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;
- 5-chloro-*N*-{1-[(hydroxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;
- 5 5-chloro-*N*-[(1*R*,2*R*)-1-({[(2-hydroxyethyl)(methyl)amino]acetyl}amino)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;
- 5-chloro-*N*-[(1*R*,2*R*)-1-({[(2-hydroxyethyl)(phenylmethyl)amino]acetyl}amino)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;
- 5-chloro-*N*-((1*R*,2*R*)-1-[(3-hydroxypiperidin-1-yl)acetyl]amino)-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;
- 10 5-chloro-*N*-((1*R*,2*R*)-1-[(3-hydroxypyrrolidin-1-yl)acetyl]amino)-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;
- N*-[(1*R*,2*R*)-1-({[bis(2-hydroxyethyl)amino]acetyl}amino)-2,3-dihydro-1*H*-inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide;
- 15 *N*-{1-[(aminoacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide;
- N*-{1-[[[(3*S*)-3-amino-3-carboxypropanoyl]amino]-2,3-dihydro-1*H*-inden-2-yl]-5-chloroindole-2-carboxamide;
- 5-chloro-*N*-((1*R*,2*R*)-1-[(chloromethyl)sulfonyl]amino)-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;
- 20 5-chloro-*N*-(1-[(trifluoromethyl)sulfonyl]amino)-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;
- 5-chloro-*N*-{1-[(cyanomethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;
- 5-chloro-*N*-{(1*R*,2*R*)-1-[(1*H*-tetrazol-5-ylmethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;
- 25 *N*-{(1*R*,2*R*)-1-[(2-amino-2-oxoethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide;
- N*-[(1*R*,2*R*)-1-(carboxymethylamino)-2,3-dihydro-1*H*-inden-2-yl]-5-chloroindole-2-carboxamide;
- N*-{(1*S*,2*S*)-1-[acetyl(2-thienylmethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide;
- 30 *N*-{(1*S*,2*S*)-1-[*N*-acetyl-*N*-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;

-86-

N-[(1*S*,2*S*)-1-{*N*-acetyl-*N*-[2-(ethoxycarbonyl)cycloprop-1ylmethyl]amino}-2,3-dihydro-1*H*-inden-2-yl]-5-chloroindole-2-carboxamide;

N-{(1*R*,2*R*)-1-[*N*-acetyl-*N*-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;

5 *N*-{(1*R*,2*R*)-1-[bis-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;

N-{(1*R*,2*R*)-1-[Acetyl(2-amino-2-oxoethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide;

N-{(1*R*,2*R*)-1-[*N*-(2-acetoxyacetyl)-*N*-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;

10 5-chloro-*N*-[(1*R*,2*R*)-1-(2,5-dioxomorpholin-4-yl)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;

5-chloro-*N*-((1*R*,2*R*)-1-[(2*R*)-2,3-dihydroxypropyl]amino)-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;

15 or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

11. A pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in any one of claims 1 to 10 in association with a pharmaceutically-acceptable diluent or carrier.

20

12. A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in any one of claims 1 to 10, for use in a method of treatment of a warm-blooded animal such as man by therapy.

25 13. A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in any one of claims 1 to 10, for use as a medicament.

14. A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in any one of claims 1 to 10, for use as a medicament in
30 the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man.


-87-

15. The use of a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 10, in the manufacture of a medicament for use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man.

16. The use of a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 10, in the manufacture of a medicament for use in the treatment of type 2 diabetes in a warm-blooded animal such as man.


17. A process for the preparation of a compound of formula (1) as claimed in claim 1, which process comprises:

reacting an acid of the formula (2):



(2)

or an activated derivative thereof; with an amine of formula (3):



(3)

and thereafter if necessary:

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.